Senseonics to Participate in the Guggenheim MedTech Disruptors Summit
May 21 2019 - 4:05PM
Business Wire
Senseonics Holdings, Inc. (NYSE American: SENS), a medical
technology company focused on the development and commercialization
of a long-term, implantable continuous glucose monitoring (CGM)
system for people with diabetes, today announced the company plans
to participate in the upcoming Guggenheim MedTech Disruptors Summit
in New York, NY.
Management is scheduled to present Wednesday, May 29, 2019 at
10:00am ET. Interested parties may access a live and recorded
webcast of the presentation on the “Investor Relations” section of
the company’s website at www.senseonics.com.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company
focused on the design, development and commercialization of
transformative glucose monitoring products designed to help people
with diabetes confidently live their lives with ease. From its
inception, Senseonics has been advancing the integration of novel,
fluorescence sensor technology with smart wearable devices. The
Eversense® CGM System received PMA approval from the FDA for up to
90 days of continuous use and is available in the United States.
The Eversense® XL CGM System received CE mark for up to 180 days of
continuous use and is available in Europe. For more information on
Senseonics, please visit www.senseonics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190521005873/en/
Senseonics Investor Relations Contact:Lynn Lewis or
Philip TaylorInvestor
Relations415-937-5406Investors@senseonics.com
Senseonics (AMEX:SENS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Senseonics (AMEX:SENS)
Historical Stock Chart
From Sep 2023 to Sep 2024